Abstract:Background Though many randomized control trials had examined the effectiveness and safety of taking insulin therapy with or without metformin, there are limited real-world data, especially among Chinese type 2 diabetes patients initiating basal insulin (BI) with uncontrolled hyperglycemia by oral agents. This study was designed to assess the effectiveness and safety of BI therapy combined with or without metformin in a real-world national cohort study. Methods Patients with type 2 diabetes mellitus who initiated BI treatment due to uncontrolled hyperglycemia (HbA1c >= 7 %) by oral antidiabetic drugs (OADs) were recruited in Chinese real-world settings between 2011 and 2013. A total of 12,358 patients initiated BI without bolus insulin and completed a 6-month follow-up were selected as the study population and divided into BI with metformin or BI without metformin group based on whether metformin was simultaneously prescribed or not at baseline. Propensity score adjustment was used to balance baseline covariates between two groups. A sub-analysis was also conducted among 8,086 patients who kept baseline treatment regimen during the follow-up. Outcomes were HbA1c, hypoglycemia, weight gain and insulin dose in two groups. Results 53.6 % (6,621 out of 12,358) patients initiated BI therapy concomitant with metformin. After propensity score adjustment, multivariate regression analysis controlled with number of OADs, total insulin dose, physical activity and diet consumption showed that BI with metformin group had a slightly higher control rate of HbA1c <7.0 % (39.9 % vs. 36.4 %, P = 0.0011) at 6-month follow-up, and lower dose increment from baseline to 6-month (0.0064 vs. 0.0068 U/day/kg, P = 0.0035). The sub-analysis with patients remained at same BI therapy further showed that BI with metformin group had higher HbA1c control rate (47.9 % vs. 41.9 %, P = 0.0001), less weight gain (-0.12 vs. 0.15 kg P = 0.0013), and lower dose increment during 6-month follow-up (0.0033 vs. 0.0037 U/day/kg, P = 0.0073) when compared with BI without metformin group. Conclusions In alliance with current guidelines, the real-world findings also support the insulin initiation together with metformin. Continuous patients' education and clinicians training are needed to improve the use of metformin when initiating BI treatment.

Predictors of Glycemic Control in Patients with Type 2 Diabetes: A Subgroup Analysis of the Observational Registry of Basal Insulin Treatment Study in China

Patient characteristics and 6-month dose of basal insulin associated with HbA1c achievement <7.0% in Chinese people with type 2 diabetes: results from the Observational Registry of Basal Insulin Treatment (ORBIT).

Observational Registry of Basal Insulin Treatment in Patients with Type 2 Diabetes in China: Safety and Hypoglycemia Predictors

Glycemic Control Rate of T2DM Outpatients in China: A Multi-Center Survey

Proportion and characteristics of patients with Type 2 diabetes mellitus initiating basal insulin therapy using a basal-bolus regimen

436-P: Stringent Glycemic Control and Long-Term Macrovascular Outcomes in People with Type 2 Diabetes in China—A Retrospective Study

Adherence to Blood Glucose Self-Monitoring Guidance and Glycemic Control in Chinese Patients with Type 2 Diabetes Mellitus Initiating Basal Insulin: an Mhealth-Based Prospective Cohort Study (Preprint)

Observational Registry of Basal Insulin Treatment (ORBIT) in Patients with Type 2 Diabetes Uncontrolled with Oral Antihyperglycaemic Drugs: Real-life Use of Basal Insulin in China.

Factors Associated with Glycemic Control in Type 1 Diabetes Patients in China: A Cross‐sectional Study

Non-pharmaceutical factors for poor glycemic control in 13,970 Chinese women with drug-treated type 2 diabetes: a cross-sectional survey in 77 tertiary hospitals in four Chinese cities.

The Risk Factors of Glycemic Control, Blood Pressure Control, Lipid Control in Chinese Patients with Newly Diagnosed Type 2 Diabetes _ A Nationwide Prospective Cohort Study.

Determinants for inadequate glycaemic control in Chinese patients with mild-to-moderate type 2 diabetes on oral antidiabetic drugs alone

Survey of Glycemic Control in Type 2 Diabetic Patients Treated with Human Insulin in China

Determinants of self-monitoring of blood glucose with type 2 diabetes based on 496 questionnaire surveys in China

Management status and its predictive factors in patients with type 2 diabetes in China: A Nationwide Multicenter Study: A Nationwide Multicenter Study.

Effectiveness and Safety of Basal Insulin Therapy in Type 2 Diabetes Mellitus Patients with or Without Metformin Observed in a National Cohort in China

Relationship Between Hba1c and Continuous Glucose Monitoring in Chinese Population: A Multicenter Study

Observational Study Evaluating the Effectiveness of Physician-Targeted Education for Improving Glycemic Management of Patients with Type 2 Diabetes (BEYOND II)

Determinants of poor glycemic control in Chinese men with type 2 diabetes: a cross-sectional survey of 15,427 men in 77 tertiary hospitals in China

Glycemic Control among Patients in China with Type 2 Diabetes Mellitus Receiving Oral Drugs or Injectables

PDB36 Glycemic Control and Quality of Life for Patients with Type 2 Diabetes Mellitus in China